PMC8255476_01
PMC8255476_02
Evolution of clozapine plasma level (ng/mL) for each case. Period of time before and after the introduction of fluvoxamine. J0 represents the day of the introduction of fluvoxamine.
fpsyt-12-669446-g0001.jpg
PMC8255476_06_fpsyt-12-669446-g0001.jpg
F1
At 1 day after fluvoxamine's introduction (starting at 25-50 mg/day), a drastic increase in clozapine plasma level (261 ng/mL) was observed (see Figure 1). Regarding tolerance, we did not report any side effect; a repeat blood sample was not a reason to stop the treatment, and no hematological adverse event was reported (see Supplementary Figure 1).
PMC8255476_03
Evolution of clozapine plasma level (ng/mL) for each case. Period of time before and after the introduction of fluvoxamine. J0 represents the day of the introduction of fluvoxamine.
fpsyt-12-669446-g0001.jpg
PMC8255476_06_fpsyt-12-669446-g0001.jpg
F1
At 1 day after fluvoxamine's introduction (starting at 25-50 mg/day), a drastic increase in clozapine plasma level (261 ng/mL) was observed (see Figure 1). Regarding tolerance, we did not report any side effect; a repeat blood sample was not a reason to stop the treatment, and no hematological adverse event was reported (see Supplementary Figure 1).
Algorithm.
fpsyt-12-669446-g0002.jpg
PMC8255476_06_fpsyt-12-669446-g0002.jpg
F2
An extensive screening panel was performed (see Supplementary Figure 2 for details of the screening panel).
PMC8255476_04
PMC8255476_05
Evolution of clozapine plasma level (ng/mL) for each case. Period of time before and after the introduction of fluvoxamine. J0 represents the day of the introduction of fluvoxamine.
fpsyt-12-669446-g0001.jpg
PMC8255476_06_fpsyt-12-669446-g0001.jpg
F1
At 1 day after fluvoxamine's introduction (starting at 25-50 mg/day), a drastic increase in clozapine plasma level (261 ng/mL) was observed (see Figure 1). Regarding tolerance, we did not report any side effect; a repeat blood sample was not a reason to stop the treatment, and no hematological adverse event was reported (see Supplementary Figure 1).
Algorithm.
fpsyt-12-669446-g0002.jpg
PMC8255476_06_fpsyt-12-669446-g0002.jpg
F2
An extensive screening panel was performed (see Supplementary Figure 2 for details of the screening panel).
PMC8255476_06
Evolution of clozapine plasma level (ng/mL) for each case. Period of time before and after the introduction of fluvoxamine. J0 represents the day of the introduction of fluvoxamine.
fpsyt-12-669446-g0001.jpg
PMC8255476_06_fpsyt-12-669446-g0001.jpg
F1
At 1 day after fluvoxamine's introduction (starting at 25-50 mg/day), a drastic increase in clozapine plasma level (261 ng/mL) was observed (see Figure 1). Regarding tolerance, we did not report any side effect; a repeat blood sample was not a reason to stop the treatment, and no hematological adverse event was reported (see Supplementary Figure 1).
Algorithm.
fpsyt-12-669446-g0002.jpg
PMC8255476_06_fpsyt-12-669446-g0002.jpg
F2
An extensive screening panel was performed (see Supplementary Figure 2 for details of the screening panel).